- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05253287
Growth Hormone in Decompensated Liver Cirrhosis
Impact of Repurposed Growth Hormone Treatment on Clinical, Nutritional, Immunological and Regenerative Parameters in Decompensated Liver Cirrhosis: a Randomized Control Trial
Globally, cirrhosis and liver cancer carries a huge burden and accounts for about 3.5% (2 million) of all deaths every year. Once decompensated, i.e. development of ascites, variceal bleed, encephalopathy, and jaundice, the life expectancy is markedly reduced to a median of two years. The definitive treatment in this stage, i.e., liver transplantation is limited by cost, lack of donors, and life-long immunosuppression.
In addition to complications due to portal hypertension and hepatic insufficiency, decompensated cirrhosis is associated with malnutrition, sarcopenia, immune dysfunction, and impaired regeneration. Patients with cirrhosis are growth hormone (GH) resistant, with reduced insulin-like growth factor, which are linked to malnutrition and poor liver regeneration in cirrhosis. Diverse preclinical and clinical investigations in vitro and in vivo, have shown a benefit of GH in GH deficient, elderly and HIV positive patients. GH therapy in cirrhosis has been shown to improve nitrogen economy and to improve the GH resistance in a small pilot study by Donaghy et al. Also, GH therapy of short duration has shown to increase IGF1 levels, IGFBP-3 levels in patients of cirrhosis. GH therapy has also been shown to improve liver regeneration and protein synthesis after hepatectomy in patients of HCC with cirrhosis. However, there is a scarcity of data on clinical impact of long term administration of GH therapy in patients of cirrhosis. Hence, we undertook the present study to study the effect of growth hormone on clinical outcomes, malnutrition, immune cells and liver regeneration in patients with cirrhosis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Liver disease accounts for approximately 3.5% all deaths per year around the world, cirrhosis being the 11th most common cause of death globally. Liver cirrhosis is the final stage of all progressive and chronic liver diseases which progresses from asymptomatic compensated stage to decompensated at a rate of 5% to 7% each year. The major complications of liver cirrhosis are portal hypertension, ascites, spontaneous bacterial peritonitis (SBP), variceal bleed, hepatic encephalopathy (HE), hepatocellular carcinoma (HCC). Moreover, complications like protein-calorie malnutrition associated with sarcopenia, cirrhosis associated immune dysfunction (CAID) and impaired regeneration further adds to reduced survival. Liver transplantation is the only effective treatment for these patients but it is limited by resources, costs, expertise, and organ availability. Malnutrition is common in cirrhosis with prevalence ranging from 65 to 100%. Sarcopenia or loss of skeletal muscle mass is the major component of malnutrition in cirrhosis with prevalence of 40- 60%. Independent clinical consequences of sarcopenia in cirrhosis include lower survival, quality of life & increases risk of complications. Lack of improvement with nutritional supplementation is observed which may be attributed to GH resistance in cirrhotic patients further worsening sarcopenia.
CAID is a dynamic phenomenon, comprised of both increased systemic inflammation and immunodeficiency, ultimately leading to 30% mortality. Immunodeficiency in cirrhosis roots from deranged local immunity of liver, compromised immune surveillance of the liver and impairments in systemic immune cells (innate as well as adaptive).The systemic inflammation results from persistent immune cell stimulation due to enhanced gut translocation leading to increased production of various proinflammatory cytokines.
Liver regeneration is a complex and unique process. Hepatocytes have a remarkable capacity to meet the replacement demands during cellular loss. However, this regenerative capacity is overwhelmed during the late stage of acute liver injury, compromised in chronic liver injury, and lost in acute-on-chronic liver injury.
GH administration have been shown to improve sarcopenia, immune functions & regeneration in clinical studies and preclinical studies both in vitro and in vivo. Patients with chronic liver diseases are GH resistant i.e. they have high GH levels & low levels of IGF-1. So, in this study, we will investigate the impact of growth hormone on additional parameters including clinical outcomes, immunological profile and select parameters of liver regeneration in decompensated liver cirrhosis.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Nipun Verma, DM
- Phone Number: 9914208562
- Email: nipun29j@gmail.com
Study Contact Backup
- Name: Parminder Kaur, M.SC
- Phone Number: 8288053620
- Email: pinderbrar888@gmail.com
Study Locations
-
-
UT
-
Chandigarh, UT, India, 160012
- Recruiting
- Postgraduate Institute of Medical Education and Research
-
Contact:
- Nipun Verma, MD, DM
- Phone Number: +919914208562
- Email: nipun29j@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age above 18 years.
- Patients having confirmed diagnosis of decompensated cirrhosis, any etiology.
- Patients having given an informed and written consent for participation in the study.
Exclusion Criteria:
- Acute on chronic liver failure.
- Diagnosis of concomitant hepatocellular carcinoma or other active malignancy.
- Severe cardiac dysfunction NYHA grade III/IV, Chronic obstructive pulmonary disease GOLD C or above.
- Active alcohol abuse in last 3 months.
- Known hypersensitivity to GH.
- Human immunodeficiency virus seropositivity.
- Patients on antiviral therapy for HCV, HBV or corticosteroid for autoimmune hepatitis those who have received it within the last 6 months.
- TIPS insertion within 6 months prior to study inclusion.
- Pregnancy & lactation.
- Uncontrolled diabetes (Hb A1c ≥ 9) or diabetic retinopathy.
- Active sepsis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Standard Medical treatment
Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
|
|
EXPERIMENTAL: Growth hormone + Standard medical therapy
GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
|
GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complication free survival
Time Frame: 12 Month
|
Complications of cirrhosis - Ascites, Hepatic encephalopathy, Gastrointestinal bleeding, Bacterial infections, Acute kidney injury
|
12 Month
|
Transplant free survival
Time Frame: 12 Month
|
Transplant free survival where event is transplant or death
|
12 Month
|
Incidence of complications of cirrhosis and infections
Time Frame: 12 Month
|
Complications of cirrhosis - Ascites, Hepatic encephalopathy, Gastrointestinal bleeding, Bacterial infections, Acute kidney injury
|
12 Month
|
Change in disease severity scores (CTP score)
Time Frame: 12 Month
|
The Child-Turcotte-Pugh (CTP) score is used to assess the prognosis of patients with cirrhosis.
The Pugh-Child score is determined by scoring five clinical measures of liver disease (Encephalopathy, Ascites, Albumin, Bilirubin and INR).
A score of 1, 2, or 3 is given to each measure, with 3 being the most severe.
|
12 Month
|
Change in disease severity scores (MELD Na)
Time Frame: 12 Month
|
The MELD/Na score is a scoring system for accessing the severity of chronic liver disease using values as serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time and sodium, to predict survival.
|
12 Month
|
Treatment related adverse events
Time Frame: 12 Month
|
Any adverse events related to growth hormone
|
12 Month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of sarcopenia
Time Frame: 12 Month
|
Sarcopenia will be assessed by calculation of Skeletal muscle index by taking cross sectional area of the psoas muscle at the level of the third lumbar vertebra on abdomen CT scans.
|
12 Month
|
Change in liver frailty index
Time Frame: 12 Month
|
LFI (Liver frailty index) will be calculated by FrAILT software©
|
12 Month
|
Change in nitrogen balance
Time Frame: 12 Month
|
Nitrogen balance will be calculated by using formula - Nitrogen intake - nitrogen output
|
12 Month
|
Change in myostatin levels
Time Frame: 12 Month
|
Myostatin in the serum will be measured in serum
|
12 Month
|
Change in Functional capacity of monocytes
Time Frame: 12 Month
|
Phagocytic capacity of monocytes will be assessed using flow cytometry
|
12 Month
|
Change in Functional capacity of Neutrophils
Time Frame: 12 Month
|
Phagocytic capacity of neutrophils will be assessed using flow cytometry
|
12 Month
|
Change in cytokine levels
Time Frame: 12 Month
|
Pro-inflammatory and anti-inflammatory cytokines will be assessed in serum using Multiplex ELISA.
|
12 Month
|
Immunophenotyping of T cells
Time Frame: 12 Month
|
Immunophenotyping of T cells will be performed using flow-cytometry.
|
12 Month
|
Immunophenotyping of B cells
Time Frame: 12 Month
|
Immunophenotyping of B cells will be performed using flow-cytometry.
|
12 Month
|
Immunophenotyping of NK cells
Time Frame: 12 Month
|
Immunophenotyping of NK will be performed using flow-cytometry.
|
12 Month
|
Immunophenotyping of monocytes
Time Frame: 12 Month
|
Immunophenotyping of monocytes will be performed using flow-cytometry.
|
12 Month
|
Immunophenotyping of neutrophils
Time Frame: 12 Month
|
Immunophenotyping of neutrophils will be performed using flow-cytometry.
|
12 Month
|
Change in cell death markers
Time Frame: 12 Month
|
Markers of cell death - M30 & M65 will be assessed in serum using ELISA
|
12 Month
|
Change in surrogate markers for hepatic regeneration
Time Frame: 12 Month
|
surrogate markers for hepatic regeneration- Hepatocytes growth factor will be assessed in serum using ELISA.
|
12 Month
|
Collaborators and Investigators
Investigators
- Study Director: Virendra Singh, DM, Professor and Head, Department of Hepatology
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Liver Failure
- Hepatic Insufficiency
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Muscular Atrophy
- Atrophy
- Liver Diseases
- End Stage Liver Disease
- Fibrosis
- Liver Cirrhosis
- Sarcopenia
- Gastrointestinal Diseases
- Digestive System Diseases
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones
Other Study ID Numbers
- IEC-06/2021-2015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Liver Disease
-
Vanderbilt University Medical CenterEnrolling by invitationEnd Stage Liver DIseaseUnited States
-
Virginia Commonwealth UniversityCompletedEnd Stage Liver DIseaseUnited States
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonCompletedEnd-stage Liver DiseaseUnited Kingdom
-
Proteonomix, Inc.University of Medicine and Dentistry of New Jersey; NumodaUnknownEnd Stage Liver DIseaseUnited States
-
University of ZurichUniversity Ghent; University Hospital of Sao Paulo, BrazilCompleted
-
RenJi HospitalNot yet recruitingEnd Stage Liver DIsease
-
Mayo ClinicRecruiting
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Huashan HospitalRecruiting
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
Clinical Trials on Growth Hormone
-
The University of Texas Medical Branch, GalvestonCompletedMild Cognitive ImpairmentUnited States
-
University of PennsylvaniaNational Institute on Aging (NIA)TerminatedAging | Hormone DeficiencyUnited States
-
Massachusetts General HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of WashingtonNational Institute on Aging (NIA)CompletedAging | Mild Cognitive ImpairmentUnited States
-
Massachusetts General HospitalCompleted
-
Massachusetts General HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHealthy VolunteersUnited States
-
University of PennsylvaniaCompletedCongestive Heart FailureUnited States
-
Versartis Inc.Completed
-
Rabin Medical CenterPfizerCompleted
-
Massachusetts General HospitalActive, not recruitingObesity | Fatty Liver | Liver Fat | Obesity, Abdominal | Non-Alcoholic Fatty Liver DiseaseUnited States